The facts about participating in clinical research and our ongoing studies:
First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.
Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.
For more information, please call: 954-366-0277.
CURRENTLY ENROLLING CLINICAL TRIALS
HOLLYWOOD NEUROLOGY
To participate or refer a patient, call 954-366-0277; Ext 120 – Jorge, Ext 121 – Rebecca, Ext 124 – Lucy, Ext 122 – Muskaan
Clinical Coordinators: Jorge Riveros, IMG, CCRC • Rebecca Nembhard, CCRC • Lucy Vargas, MA, CRC • Muskaan Ochani, BS, CRC
Jazz: Everest Essential Tremor – A Phase 2b, 12-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults with Moderate to Severe Essential Tremor for people 18-80 years of age.
Sage: Essential Tremor – A Phase 2 Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor in adults with mild to moderate bilateral tremor for at least 3 years. Ages 18-80. 5 year open label extension after completion of the core study.
Sage: Alzheimer’s Disease/Memory loss – Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants with Mild Cognitive Impairment or Mild Dementia Due to Alzheimer’s Disease ages 50-80
Biogen Envision: Alzheimer’s Disease – A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants with Alzheimer’s Disease, ages 60-85.
Axsome: Migraine – An open label, multidose evaluation of the efficacy and safety of AXS-07 (Meloxican and Rizatriptan) for the Acute treatment of Migraine in adult with an inadequate response to oral CGRP inhibitors. Patients over 18 years of age.
Axsome: Alzheimer’s with Agitation ADVANCE-2 – A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Alzheimer’s Disease Agitation for 6 weeks, followed by an Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects with Dementia of the Alzheimer’s Type ages 65-90.
Ipsen Chronic Migraine – A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants 18 years or older.
Ipsen Episodic Migraine – Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants 18 years or older.
SUNRISE OFFICE NEUROLOGY – MS STUDIES
To participate or refer a patient –Call 954-475-8171 Ext 134 (Muskaan)
